Alex Denner (Sarissa Capital Management)
June 21, 2023 11:26 AM EDT
People

Saris­sa's Alk­er­mes board re­place­ments large­ly fail to win sup­port from share­hold­er firms, which cite Bio­gen board moves

Kyle LaHucik

Senior Reporter

Alex Den­ner, the in­vestor be­hind the ac­tivist firm Saris­sa Cap­i­tal Man­age­ment, is not win­ning much sup­port for his board up­heaval plans at Irish drug­mak­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times